The candidate-vaccine Abdala developed by Cuba against the Covid-19, the first created in Latin America, displays effectiveness of 92.28% against the disease, announced Monday, June 21 the laboratory which developed it.
“Abdala, CIGB’s Cuban vaccine candidate, shows 92.28% efficacy after three doses,” state-owned pharmaceutical group BioCubaFarma, on which the Center for Genetic and Biotechnological Engineering (CIGB ). Abdala, in the final phase of clinical trials, must receive official authorization from the Cuban authorities in late June or early July.
The news was announced in-person to Cuban President Miguel Diaz-Canel, who then congratulated himself on Twitter: “Struck by two pandemics (the Covid and the blockade), our scientists at the Finlay Institute and the CIGB have overcome them all. obstacles and gave us two very effective vaccines: Soberana 2 and Abdala “.
On Saturday, the Finlay Institute of Immunization announced that its candidate, Soberana 2, displays an efficiency of 62% after the injection of two of its three doses. It is a result “comforting” because it takes into account the variants which already circulate in the Caribbean country, had declared to the local press Vicente Verez, director of the institute. This candidate should also receive the official green light shortly.
Their next approval will make them the first anti-coronavirus vaccine developed and produced in Latin America, even though researchers have repeatedly denounced the difficulties encountered due to the US embargo in effect since 1962 and reinforced under the Trump administration.
The Cuban government aspires to have 70% of the 11.2 million inhabitants vaccinated by August, and the entire population before the end of the year. Due to the embargo, Cuba began to develop its own drugs in the 1980s. Of the thirteen vaccines in its vaccination program, eight are locally produced.